Vulnerable atherosclerotic plaques are responsible for most cardiovascular diseases (CVDs). Folate receptor (FR) positive activated macrophages were thought to be a prominent component in the development of vulnerable plaque. The objective of this study is to develop folate conjugated two-dimensional (2D) Pd@Au nanomaterials (Pd@Au-PEG-FA) for targeted multimodal imaging of the FRs in advanced atherosclerotic plaques. Pharmacokinetic and imaging studies (single photon emission computed tomography (SPECT), computed tomography (CT) and photoacoustic (PA) imaging) were performed to confirm the prolonged blood half-life and enrichment of radioactivity in atherosclerotic plaques. Strong signals were detected in vivo with SPECT, CT and PA imaging in heavy atherosclerotic plaques, which were significantly higher than those of the normal aortas after injection of Pd@Au-PEG-FA. Blocking studies with preinjection of excess folic acid (FA) could effectively reduce the targeting ability of Pd@Au-PEG-FA in atherosclerotic plaques, further demonstrating the specific binding of Pd@Au-PEG-FA for plaque lesions. Histopathological characterization revealed that the signal of probe was in accordance with the high-risk plaques. In summary, the Pd@Au-PEG-FA has favorable pharmacokinetic properties and provides a valuable approach for detecting high-risk plaques in the presence of FRs in atherosclerotic plaques.
Introduction
Atherosclerosis is one of the leading causes for a majority of fatal cardiovascular diseases (CVD), including myocardial infarction and stroke [1, 2] . The development of non-invasive molecular imaging has opened a new avenue for early accurate detection of atherosclerotic plaques, which is essential for taking appropriate intervention strategies to reduce cardiovascular risk [3] [4] [5] .
Traditionally, detection techniques used for detecting atherosclerosis include computed tomography (CT), intravascular ultrasound (IVUS), quantitative coronary angiography (QCA) and magnetic resonance imaging (MRI), which cannot effectively detect atherosclerotic lesions at the cellular level and disclose lesion features. For more complex characterizations of biological activity, positron emission tomography (PET) and single photon emission computed tomography (SPECT) has evolved considerably and played increasingly influential roles in providing additional prognostic value for characterizing cardiovascular risk. To date, various types of probes for PET or SPECT have received significant attention for cardiovascular imaging. 18 F-NaF can be used to image early stages of plaque formation via calcium deposition [6] . 2-deoxy-2-[ 18 F]fluoro-d-glucose ([ 18 F]FDG) and 2-deoxy-2-[ 18 F]fluoro-d-mannose ([ 18 F]FDM) have been proposed for imaging of activated macrophages [7] . For the effective diagnosis of atherosclerosis, promising receptors imaging have also been applied. For instance, 99m Tc-annexin A5 (imaging the apoptosis and thrombosis), 99m Tc-labeled anti-lectinlike oxidized low-density lipoprotein receptor 1 antibody (detects the lectinlike oxidized low-density lipoprotein receptor 1), 99m Tc/ 18 F labeled RGD-based agents (high affinity for integrin αvβ3 receptors in neovessel-rich atherosclerotic plaques), 68 Gapentixafor (imaging CXCR4 receptor expressed on inflammatory cells) and 68 Ga-DOTATATE (high-specificity binding affinity for somatostatin receptor subtype-2), have been developed to investigate the expression of the relevant receptors during developmental stages of atherosclerotic plaque [8] [9] [10] [11] [12] .
For the diagnosis of CVD, there is a pressing need to evaluate and predict the rupture of vulnerable atherosclerotic plaques effectively, but remain practically challenging. Probes with high avidity for multiplying numbers of inflammatory macrophages in atherosclerosis and myocardial infarction can provide an important indicator of vulnerability for researchers [1, 13] . Folate receptor (FR) is deemed to be a preferable marker for detecting a variety of inflammatory diseases and tumor lesions [14] . Some reports have elucidated the interactions between FR and vulnerable plaques [8, 15, 16] . A peptide derivative of folic acid (FA) probe 99m Tc-EC20 was used to image the pathological site by targeting FR-positive activated macrophages, which were thought to be a prominent component in the development of vulnerable plaque [8, 14] .
Detection of vascular plaques is challenging because of the small size of target, complex biological activities and low probes uptake in lesions. While current imaging modalities are often limited by inadequate sensitivity and specificity. Functional nanomaterials for the site-specific targeting are constantly springing up, which offer possible solutions to certain shortages of conventional strategies and traditional small molecule agents [13, [17] [18] [19] . Specific nanosystems are probably more suitable for detection of atherosclerotic plaque because of their multimodal detection (fine-tunable properties), high binding affinity (multivalency of targets) and theranostic moieties (combined diagnostic and therapeutic capacities). In this regard, nanotechnology provides feasibility of visualizing the morphological changes (lesion volume and fibrous cap thickness) and disclosing the biological aspects (molecular composition of plaques and stages of disease progression) with high temporal and spatial precision. These multiple and quantitative molecular imaging techniques would facilitate rigorous validation of lesions, guide the current anti-inflammatory therapy and assist the development of novel treatment drugs.
To optimize the efficiency of nano-probes and minimize the accumulation in healthy organs, researchers would need to find more appropriate nanocarriers and optimal surface modification methods [20] [21] [22] . Ultrathin two-dimensional (2D) Pd@Au nanosheets with favorable pharmacokinetics have the potential to enable early detection [23] [24] [25] . By comparison, we've found that the geometry of nanoprobes played an important role in their bio-behaviors. In our previous study, with an approximate hydrodynamic size, the uptake of Pd@Au in tumor site was higher than that of spherical Au nanoparticles [23] . The purpose of the present study was to assess the feasibility of detecting progression of plaques by forming a 2D multifunctional platform with attractive component (FA) on the surface and assessing the target specificity to activated macrophages, particularly through FR receptors (as shown in Fig. 1(a) ). Comparing with the previously reported small-molecule FR-targeted probes, the test result shows that superior pharmacokinetic profiles of ultrathin 2D Pd@Au nanosheets is a key to achieve the enhancement effect.
Methods
An expanded materials and methods section is available in the Electronic Supplementary Material (ESM).
Animal models
Apoliprotein E knockout (ApoE −/− ) mice with atherosclerotic aortas induced by a high fat plus high cholesterol (HFHC, 10% lard, 1.25% cholesterol) diet and normally fed adult C57BL/6 control mice (wild-type mice) were used as murine models in this research. Mice were provided by Beijing Huafukang Bioscience Co., Ltd. They were housed in a SPF laboratory animal facility under a 12 h light/dark cycle and fed a chow-diet for a week to suit the environment. Then wild-type mice were fed a chow-diet, however, ApoE −/− mice were placed on a HFHC diet for a period. All animal care and experimentations were approved by Xiamen University's Animal Care and Use Committee.
MicroSPECT imaging
Briefly, 37 MBq/200 μL 125 I-Pd@Au-PEG-FA (containing 200 μg Pd@Au nanosheets) was injected via a lateral tail vein of each mouse. Sodium iodide (about 2 mg) was given to saturate the thyroid gland 10 min prior to the 125 I-Pd@Au-PEG-FA injection. SPECT imaging of ApoE −/− mouse was performed at 30 min, 2, 4 and 8 h p.i. by using a nanoScan-SPECT/CT preclinical scanner. Healthy wild-type mice were used as control groups. The blocking study was performed by preinjection of blocking agent (200 μg FA per mouse) 15 min prior to the intravenous injection of 125 I-Pd@Au-PEG-FA injection. The SPECT imaging of ApoE −/− mice after tail vein injection (2 h p.i.) of Na 125 I and 125 I-Pd@Au-PEG (without FA moiety for FR targeting) were studied as control. During the scanning, mice were anesthetized with 3% isoflurane. The acquiring parameters were as follows: energy peak of 28 keV for 125 I, window width of 30%, matrix of 256 × 256, medium zoom, and 45 s per frame. For quantitation of radioactive signals in mouse aortas and other tissues, ROIs on the SPECT images were drawn and counted.
CT imaging
For in vitro CT imaging, phantoms with different concentration of Pd@Au-PEG-FA were scanned and the data were analyzed using the Hounsfield units (HU) for regions. For in vivo CT imaging, 200 μL Pd@Au-PEG-FA (400 μg Pd@Au nanosheets) was injected via a lateral tail vein of each mouse. CT imaging was performed at 30 min, 2, 4 and 8 h p.i. CT data were acquired using an X-ray voltage biased to 50 kVp with a 670 μA anode current, and the projections were 720°.
Ex vivo autoradiography
After SPECT imaging with 125 I-Pd@Au-PEG-FA at 8 h p.i., the atherosclerotic lesion uptake was quite specifically identified by autoradiography. The aortas were excised and exposed to a storage phosphor screen for 2 h. After that, the screen was scanned using a Cyclone Plus storage phosphor system.
Ultrasound (US) and photoacoustic (PA) imaging
Different concentrations of Pd@Au-PEG-FA in tubes were visualized using Endra Nexus128. Acquiring parameters were as follows: 120° per scan, 30 pulses per angle, laser wavelength of 800 nm.
In vivo US and PA imaging were used to monitor localization of the probes in focal areas. Depilatory cream was used to remove the hair of the chest and abdomen of plaque-bearing ApoE −/− mice (n = 5). Before and after an intravenous injection of 200 μL Pd@Au-PEG-FA (400 μg Pd@Au nanosheets), US and PA imaging of aortic arch were performed on a Vevo LAZR-X Imaging System (FUJIFILM VisualSonics Inc.). During the imaging time, mice were anesthetized using isoflurane and spontaneous breathing was maintained. US imaging was performed using B-mode at a frequency of 40 MHz, 2D power of 100%, and 2D gain of 19 dB. PA signals of Pd@Au-PEG-FA were collected using wavelength at 800 nm, PA power of 100%, and PA gain of 40 dB. US-assisted localization was used to locate the anatomical feature of the chest area. PA intensities of ROIs were quantified and compared. After in vivo imaging, ex vivo US and PA imaging were further carried out to compare the difference of PA signal intensities between the abdominal aortas of ApoE −/− mice and normal mice. 
Biodistribution and blood half-life test

Safety evaluation
The safety of nanomaterials has been always of great concern. The cytotoxicities of the Pd@Au-PEG-FA nanosheets were tested by MTT assay in 293T (human embryonic kidney cells) and LO2 cells (normal human hepatocyte). To assess the safety of Pd@Au-PEG-FA, histological H&E staining was investigated two weeks after the injection of Pd@Au-PEG-FA (500 μg Pd@Au nanosheets).
Results
Preparation of probes
The preparation of the desired probes is displayed in Fig. 1(b) . To prepare Pd@Au-PEG-FA nanosheets, it is important to synthesize the PEG precursor ( Fig. S1 in the ESM). Nuclear magnetic resonance ( 1 H NMR, Fig. S2 in the ESM) and Fourier transform infrared spectrum (FT-IR, Fig. S3 in the ESM) were used to verify the structure of FA-PEG-SH. It showed characteristics of the PEG group in the FA-PEG-SH through the 1 H NMR. The peak for C-O-C ether asymmetric stretching appeared at 1,088 cm −1 and the stretching vibration of alkyl group appeared at 2,908 cm −1 , which don't exist in the FA molecular structure.
Morphologies and sizes of Pd@Au and Pd@Au-PEG-FA nanosheets were characterized by dynamic light scattering (DLS), transmission electron microscopy (TEM). As shown in the Figs. 2(a), 2(b) and 2(e), the Pd@Au and Pd@Au-PEG-FA nanosheets had mean diameters of 26 and 31 nm, respectively. This hexagonal Pd@Au nanosheet has a plate-like shape and 7 nm thickness, with a molar ratio of Au/Pd as 10:1. The atomic compositions of Pd@Au were furthered confirmed by energy-dispersive X-ray (EDX) spectroscopy ( Fig. 2(b) ), indicating the successful epitaxial growth of Au on the surface of Pd nanosheets. Meanwhile, the interaction of halide ions with Au offered the thought and method for radioiodination, which didn't affect either the size or morphology of nanoprobes. The thiol-Au or thiol-Pd bonds provides an effective way and stable mode to load functional PEG. Through the UV-Vis-NIR spectrum of Pd@Au-PEG-FA ( Fig. 2(c) ), the introduction of FA onto the nanosheet surface was verified. Comparing the UV absorption peaks of FA and Pd@Au-PEG-FA, the absorption peak at 286 and 360 nm showed that the FA-PEG-SH was prepared and introduced into the nanosheets successfully. The standard curve was established between FA concentration and absorbance, and it was estimated that 1 mg Pd@Au nanosheets contain about 82 μg FA ( Fig. S4 in the ESM). Compared to Pd@Au, the nanosheets modified by FA-PEG-SH possessed better dispersibility and steady dispersion was maintained after radiolabeling ( Fig. 2(f) ).
The labeling process 125/131 I-Pd@Au-PEG-FA had the advantages of mild condition (room temperature), quantitative yield (nearly 100% radiochemical yield and radiochemical purity) and short reaction time. The specific activities of 131 I-and 125 I-labeled Pd@Au-PEG-FA were calculated as 9.25 and 185 kBq/μg, respectively. 131 I-Pd@Au-PEG-FA was identified by TLC with a polyamide film/saline system ( Fig. 2(d) ). The 131 I-Pd@Au-PEG-FA stayed at the point of origin (Rf: 0-0.1) and the Rf of Na 131 I was 0.3-0.4. As shown in Fig. S5 in the ESM, 131 I-Pd@Au-PEG-FA had good stability in PBS, saline and serum. The in vitro stabilities of 131 I-Pd@Au-PEG-FA in H2O and mice serum were further confirmed by dialysis experiment (Fig. S6 in the ESM). And the surface labeling with iodide ions had no effect on the size of materials ( Fig. 2(e) ).
Histopathological characterization of animal models
To confirm that some representative indications are upregulated in atherosclerotic plaques of ApoE −/− models, we stained serial sections of aortic root, arcus aortae, thoracic and abdominal aorta. The results demonstrated that the atherosclerotic lesions were concentrated in the arcus, thoracic and abdominal aorta. Lesions of atherosclerosis were observed in the ApoE −/− mice fed on the HFHC diet ( Fig. 3) but not in the control mice ( Fig. S7 in the ESM). ORO effectively stained the hydrophobic and neutral lipids in the atherosclerotic plaques that developed throughout the aorta and its principal branches, including the aortic root, the arcus aorta, the branches of brachiocephalic artery and the right common carotid artery, both renal arteries, lower abdominal and femoral arteries ( Fig. 3(a) ). For H&E and ORO stain, as shown in Figs. 3(b1) and 3(b2), several lesions of different stages were visible along the arcus aorta, branches of the brachiocephalic artery and abdominal aorta. We observed that, after 6 months of a western diet, some advanced lesions in the arcus aortae of ApoE −/− mice appeared more complex and prone to rupture, with larger extracellular lipid pool, necrotic core, thinner fibrous cap and deformed intima. Extensive atherosclerosis plaques were observed in the lesser curvature, immunohistochemical staining of anti-CD68 showed that plenty of macrophages were gathered together under the intima or clustered around the necrotic cores, FR expression significantly increased in these areas (Figs. 3(b3) and 3(b4)), and was colocalized with macrophages ( Fig. 3(b5) and Fig. S8 in the ESM). In order to distinguish stable and rupture-prone plaques, immunofluorescent staining of endothelium and SMC were accomplished. FR high expression lesions had significantly reduced endothelium cells and SMC in the fibrous cap of the lesions, and larger necrotic cores were observed in the plaques, shown a type of plaque morphology that was potentially advanced to rupture (Figs. 3(b6) and 3(b7) ). 
Cell experiment
Detection of foam cell formation was performed in our study. ORO stainings of the lipid-laden macrophages were conventionally practiced ( Fig. S9(a) in the ESM). After incubation with ox-LDL, pronounced lipid droplets accumulation was observed in a majority of the macrophages. By flow cytometry analysis ( Fig. S9(b) in the ESM), a significantly higher level of association of expression of FR-β with foam cells occurred after incubation of Raw264.7 cells with ox-LDL (the positive expression rate was up to 75% from 26.4%). The results of immunofluorescent staining (Figs. S9(c) and S9(d) in the ESM) demonstrated the high FR-β expression on foam cells but not on quiescent macrophages. These data are also consistent with the previous studies of the correlation between FR-positive macrophages and plaque vulnerability [8, 15] .
As shown in Fig. S10 in the ESM, 131 I-Pd@Au-PEG-FA showed good merits in the cell uptake, the observed cell uptake of 131 I-Pd@Au-PEG-FA was increased gradually. By comparison, pre-incubation of free FA in activated macrophages and Raw264.7 macrophages without ox-LDL resulted in a relatively low cell uptake, which indicated that 131 I-Pd@Au-PEG-FA could target the FR specifically.
SPECT imaging
In vivo SPECT images showed obvious 125 I-Pd@Au-PEG-FA signal in regions of aortic arches and abdominal aortas of 6 M ApoE −/− mice ( Fig. S11(a) in the ESM). The visualization of probe biodistribution in atherosclerotic plaques at 8 h was consistent with excised anatomic images. By drawing ROI, activity in the atherosclerotic lesion was significantly higher than that in normal regions. Statistically, as seen in Fig. S11(b) in the ESM, the artery/background ratio was 2.20 ± 0.38 at 30 min p.i. and remained at a high level (1.94 ± 0.19) at 8 h p.i. As predicted, regions of 125 I-Pd@Au-PEG-FA enrichment were found to correlate with sites of macrophage concentration from histologic data. Moreover, the experimental animals also exhibited high uptake of FR-targeted nanosheets in their kidneys, which was consistent with the case that FRs were high-expressed in kidney tissues. Importantly, for blocking study, when preinjected with excess FA, the radioactivity signal of aortae was reduced to near-background levels (as shown in Figs. S11(b) and S12(a) in the ESM, artery/background ratio was 1.08 ± 0.05 at 2 h p.i.), known to reach the atherosclerotic lesion by the passive targeting mechanism. SPECT imaging of 125 I-Pd@Au-PEG-FA in normal mice was served as a control group and a low level of radioactive iodine was detected in aortae ( Fig. S12(b) in the ESM). Similarly, no specific recognition and uptake were observed in the Na 125 I and 125 I-Pd@Au-PEG groups (Figs. S12(c) and S12(d) in the ESM).
To study the atherosclerotic model in different stages, SPECT imaging of ApoE −/− and wild-type mice were investigated at 8 h p.i. (Fig. 4(a) ). Radioactivity accumulation in whole aortas was found in 6 M ApoE −/− mice much higher than that of 2 M model and wild-type groups. The uptake ratios of arteria to background were 1.55 ± 0.11, 1.94 ± 0.20 and 1.1 ± 0.12 in 2 and 6 M atherosclerotic, and wild-type mice, respectively ( Fig. 4(b) ). To reflect the uptake in severe atherosclerosis plaque more effectively, we contrasted the maximal radioactivity of artery in different groups and noticed a definite difference between ApoE −/− and wild-type groups (Fig. 4(c) ). These experiments prove the probe's differentiating effects for the severity of plaques.
Ex vivo autoradiography
Radiologically, colocalization of agents with atherosclerotic plaques was determined by autoradiography ( Fig. 4(d) ) showed significantly high uptake in the artery of ApoE −/− group. For 6 M ApoE −/− mice, the presence of atherosclerotic plaques predominantly located at the aortic arch and the supra-aortic vessels. For 2 M ApoE −/− mice, the artery uptake less than 6 M ApoE −/− mice but higher than that of the wild-type group. These results were consistent with the SPECT images. About 3.39-fold higher activity density in atherosclerotic vascular areas of 6 M ApoE −/− mice than that in wild-type mice ( Fig. 4(e) ).
CT imaging
To assess the potential of Pd@Au-PEG-FA nanosheets as an effective CT contrast agent, the CT signal attenuation of Pd@Au-PEG-FA nanosheets with different concentrations was evaluated ( Fig. 5(a) ). The CT values increased with the concentration of Pd@Au nanosheets and kept a well-correlated linear relationship ( Fig. 5(b) ). For in vivo CT imaging, the changes of aorta before and after intravenously injection of Pd@Au-PEG-FA were mainly observed. As shown in Fig. 5(c) , the aorta was clearly illustrated with high contrast after 30 min injection, which is an evidence for the high accumulation of nanoprobe in atherosclerotic vascular sites.
US and PA imaging
Different concentrations of Pd@Au-PEG-FA in phantoms were detectable by the PA imaging ( Fig. S13 in the ESM). Accurate localization of Pd@Au-PEG-FA was further confirmed by in vivo PA imaging and aortic arch was ensured through US imaging assisted location ( Fig. 6(a) ). As shown in Fig. 6(b) , enhanced PA signals were acquired at different time-points post-injection (2, 4 and 8 h). The PA signal intensity and contrast (signalto-background ratio) in the region of the aortic arch increased over time ( Fig. 6(c) ). The PA contrast increased from 5.7 (2 h p.i.) to 12.8 (8 h p.i.) due to the clearance of background signals and cardiovascular selectivity of Pd@Au-PEG-FA, coinciding with in vivo SPECT imaging results. As displayed in Fig. 6(d) , ex vivo PA imaging further determined that a larger proportion of probes accumulated in atherosclerotic vessels than normal vessels. As a result, PA contrast in atherosclerotic lesion had a significantly higher ratio than that in the control group (57.02 ± 5.63 vs. 28.37 ± 8.19).
Biodistribution and blood half-life test
To evaluate the 131 I-Pd@Au-PEG-FA uptake in living organisms, we performed biodistribution using BALB/c mice. As you can see in Fig. 7(a) , uptake in liver, lung and spleen decreased approximately with the time change. Obvious activity uptake (12.58%ID/g) in the stomach was observed at 12 h p.i., and this corresponded with the case seen on the SPECT images. Mild radioactivity uptake in the thyroid was within an acceptable range. High activity in the kidneys indicated that 131 I-Pd@Au-PEG-FA had the ability to target FR and can be cleared predominantly through the renal pathway. As a nanomaterial with special morphology, 131 I-Pd@Au-PEG-FA exhibited prolonged blood circulation and the t1/2z was 11.84 ± 0.69 h (Figs. 7(b) and 7(c)).
Safety evaluation
Also noteworthy is the biological safety of the radioiodinated Pd@Au-PEG-FA. The dosage-dependent relationships on 293T (human embryonic kidney cells) and LO2 cells (normal human hepatocyte) were examined by MTT assay. No noticeable cytotoxicity was observed in the range of concentration studied (Fig. S14 in the ESM) . Besides, the histological H&E staining did not discover significant pathological changes two weeks after vein injection of 500 μg Pd@Au-PEG-FA (Fig. S15 in the ESM).
Discussion
In this study, the use of an active targeting mechanism improves the specificity of Pd@Au nanosheets, implying their high potential as a precision platform for theranostics of atherosclerosis. Conventional strategies for radioiodine labeling require iodination reagents and iodine-accepting functional groups. Considering the cumbersome preparation of most radiotracers, it is critical to developing better probes with efficient reaction and high radiochemical yield. Fortunately, Pd@Au-PEG-FA can be radiolabeled with radioiodines by simply stirring for a few minutes at room temperature without any adjuvants, which brings great conveniences to the users. In addition, based on the broad application of radioiodines in nuclear medicine, the development of radioiodinated probes has a strong practical significance. It should be noted that radioactive iodine-125 was used for small-animal SPECT imaging with preclinical scanner which equipped with low energy collimators. While for clinical use, 131 I isotope would be preferred for human SPECT imaging.
Halide ions are very useful for the shape-controlled synthesis of noble metal nanocrystals, and their strong adsorption on specific facets of Au and Pd has been put more value on. In previous articles, we reported two pH-sensitive radiolabeled theranostic nanoagents using the specific adsorption of radioiodines on the surface of Pd nanosheets [24, 25] . In this study, core-shell Pd@Au nanosheets were prepared by a seeded growth method using ultra-small Pd nanosheets as seeds. In the experiment, we found that the combination of Au on the surface with radioiodines did not show pH-dependent behavior and exhibited better stability than Pd-I in vitro. However, the high stomach activity was observed from the SPECT images, indicating the stability of 131 I-Pd@Au-PEG-FA in vivo need to be further improved. This may be because iodide has a role in regulating the gastric pH. Moreover, the sodium iodide symporter (NIS) is abundant in the gastric mucosa and responsible for the iodide transport. In this case, high accumulation of iodide could be detected in the stomach. In this study, SPECT, CT and PA imaging provide powerful monitoring methods in vivo for the exact diagnosis of lesions. In practical detection, CT helps to restrict the pathological depiction more accurately. The multimodal platform integrating high sensitivity of SPECT and high resolution of CT is able to afford more overall and effective information for the clinicespecially when the hybrid SPECT/CT and PET/CT systems are becoming increasingly widespread. While, because of the low uptake ratio of nonspecific agents, high probe concentration for CT imaging limits the biomedical applications. In this work, it is to be appreciated that the Pd@Au-PEG-FA with superiorities of improved specificity efficiency helps to reduce the dosage of probes and ensure CT-detectable visual effect. In addition to multimodality imaging, the advancements in molecular imaging bring about new opportunities for the interventional molecular imaging technique [26] [27] [28] . It's worth noting that the Pd@Au-PEG-FA possesses excellent properties of photothermal conversion. Real-time infrared thermal imaging of Pd@Au-PEG-FA with different concentrations was recorded in Fig. S16 in the ESM. Based on the interventional molecular imaging technique, this function of Pd@Au nanosheets could also be used in photothermal therapy to clean out the arteries by photothermal channel switch or dissolving cholesterol-filled plaque [29] . Strong PA signal from localized Pd@Au-PEG-FA in regions with atherosclerotic lesion is feasible for providing obvious structural imaging of cardiac vasculature with high temporal and spatial precision, which offer a powerful tool for accurate image-guided interventional therapy without radiation. At the same time, the targeting ability of FA for high-risk plaques lays the foundation of accurately targeted therapy.
Although PET imaging for visualization of vascular inflammation using [ 18 F]FDG is a widely investigated strategy, radiolabeled glucose accumulation in lesions is affected by a large number of variables including weight and blood glucose levels. Besides, [ 18 F]FDG is absorbed into the normal heart and brown fat thereby affects the imaging quality seriously. In this study, 18 F-FDG PET scan was performed for comparison ( Fig. S17 in the ESM). Macrophage-rich inflammation is a character of advanced and high-risk atherosclerotic plaques and other vascular diseases that can't be neglected [1, 21, 30, 31] . Importantly, the vulnerable plaque has been found to correlate directly with the severity of CVD. A major distinction between activated and quiescent macrophages lies in their expression of FRs. Recently, some researches have discussed the one-to-one relationship between FR-positive macrophages (proinflammatory) and plaque vulnerability [8, 15] . Based on this correlation, some motivation could be provided for the diagnosis of lesion progression, severity and destabilization to reduce the risk of cardiovascular events. Furthermore, nuclear medicine imaging with high sensitivity and specificity can provide significant information for monitoring disease progression and response to therapy. In this case, more specific targeting agents for the identification of high-risk plaques are pressing need. Besides FA, this flexible framework allows different targeting moieties for various receptors or other functional ligands to be incorporated simultaneously to improve tissue-specific targeting.
For nanoprobes, dissatisfactory target specificity and slow clearance from normal tissues are worrisome problems, which limit the application of nanomaterials in theranostics. Low accumulation in non-target organs would minimize the image misinterpretation [17, 21, 31] . Fortunately, due to its special morphology, FR targeting or some other characteristics, Pd@Au-PEG-FA enriches in kidney and plaque lesion. So it's worth pondering the deeper causes, especially when compared with small-molecule probes. The small-molecule probes 99m Tc-HYNIC-D1-FA2 and 99m Tc-HYNFA used as tumor imaging agents were reported in our previous papers [32, 33] , and their SPECT images of atherosclerotic plaques were shown in Fig. S18 in the ESM. High background signals and the consequent low target-to-nontarget ratios were the most crucial factors degrading the imaging quality. The limited plaque uptakes were also observed in other radiolabeled folate derivatives (3ʹ-aza-2ʹ-[ 18 F]fluorofolic acid, 99m Tc-EC20, 111 In-EC0800, etc.) in FR-targeted atherogenesis imaging [34, 35] . Many studies have shown that blood half-life represents a key part in the bioavailability of drug [36, 37] . We hypothesize that superior pharmacokinetics (2D Pd@Au nanostructure has a long blood half-life and can keep for a long time in vivo) ensure the combination of imaging agents and targets, which result in high uptake in inflamed atherosclerotic plaques. In this study, the superiority of Pd@Au-PEG-FA was demonstrated by comparing to the 99m Tc-HYNIC-D1-FA2 and 99m Tc-HYNFA. Pd@Au-PEG-FA drastically extended the blood retention with a half-life (t1/2) of ~ 11.84 ± 0.69 h (Figs. 7(b) and 7(c)), which was partially contributed to its excellence in imaging of atherosclerotic lesion. Our previous work has demonstrated the importance of 2D morphology in enhancing tumor uptake [23] . Continual increase of PA intensity in the aortic arch is also observed in Fig. 6(c) . Another reason could be that the multimer concept is used for enhancing the plaque-targeting capability. The concentration factor exists in nanoprobes could multiply probability of probes binding to atherosclerosis plaques and result in higher plaque uptake than conventional agents. Thus, it stands to reason that cardiovascular probes could benefit from the special biological properties of ultrathin 2D nanostructures. And these strategies allowed the nanoprobes to be targeted more to the plaques and led to a significant increase in target-to-nontarget ratios.
There is no denying that nano-particle drugs still have a very long way to go to keep up with small molecule drugs in translational medicine. Therefore, we have demonstrated this enhanced blood half-life for low-molecular-weight probes, such as the derivative of Evans Blue or other portable albumin binders [36] [37] [38] . We are optimistic in improving the performance of CVD agents by using this strategy and relevant follow-up work is underway.
Conclusions
There is an unmet clinical need to quantitatively and anatomically monitor plaque progression before lesions rupture and subsequent vascular events appear. This study provides a versatile nanoplatform for sensitive and specific detection of FR-positive atherosclerotic plaques through multimodal imaging. The long-circulating and macrophage-targeted Pd@Au-PEG-FA offers colossal advantages including efficient preparation process, high target specificity, low background interference and superior sensitivity, which give advantages to potential clinical advances for management and guidance of current CVD theranostic strategies. We anticipate that the development of Pd@Au-PEG-FA for CVD will attract attention-stimulating research with a translatability to reach the clinic.
